Method and device for identifying substances capable of modulating adipicyte differentiation
CA 2472016 A1 · Owner: Genfit · Inventors: Staels, Bart
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention concerns a method for identifying compounds capable of modulating adipocyte differentiation which consists in contacting the compound to be tested with genetically modified pre-adipocyte cells overexpressing the <I>REV-ERB-ALPHA</I> receptor and measuring the adipocyte differentiation of said genetically modified cells with the adipocyte differentiation of same said genetically modified pre-adipocyte cells in the absence of said compound to be tested. The invention also concerns genetically modified pre-adipocyte cells overexpressing the <I>REV-ERB-ALPHA</I> receptor as well as the method for preparing said cells.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 17, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 17, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 17, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.